Travere Therapeutics (TVTX) Restructuring Costs (2016 - 2024)
Travere Therapeutics (TVTX) posted Restructuring Costs of $1.4 million for Q4 2024, up 1009.76% on a QoQ basis from $123000.0 in Q3 2024, and down 88.02% year-over-year from $11.4 million in Q1 2024.
Travere Therapeutics (TVTX) Restructuring Costs (2016 - 2024) Analysis & Trends
Travere Therapeutics' Restructuring Costs history runs 5 years deep, the most recent figure standing at $1.4 million for Q4 2024.
- Quarterly Restructuring Costs fell 88.02% year-over-year to $1.4 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $1.4 million (down 89.02% YoY) and the FY2024 annual result came in at $2.4 million, down 78.94% from the prior year.
- Restructuring Costs was $1.4 million for Q4 2024 at Travere Therapeutics, up from $123000.0 in the prior quarter.
- Across five years, Restructuring Costs topped out at $11.4 million in Q4 2023 and bottomed at $123000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Travere Therapeutics | 5.25 Bn | 5.25 Bn | 125.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.37 Mn |
| Sep 30, 2024 | 123,000.00 |
| Jun 30, 2024 | 653,000.00 |
| Mar 31, 2024 | 259,000.00 |
| Dec 31, 2023 | 11.39 Mn |
| Dec 31, 2018 | -242,000.00 |
| Dec 31, 2017 | 14,000.00 |
| Jun 30, 2017 | 981,000.00 |
| Mar 31, 2017 | 498,000.00 |
| Sep 30, 2016 | 5.21 Mn |